chartexchange

OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial

Newsfile | Nov 5, 2026 8:00 AM EST

Grasonville, Maryland--(Newsfile Corp. - November 5, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or the "Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has completed the requalification of drug substance used in its Phase 2b trial of OST-HER2 (Herlystic™) in the prevention of recurrence in fully resected, pulmonary metastatic osteosarcoma. The requalification is key as the Company is now able to commence the...

Read original article